596 related articles for article (PubMed ID: 11699060)
1. Systemic treatment with sympatholytic dopamine agonists improves aberrant beta-cell hyperplasia and GLUT2, glucokinase, and insulin immunoreactive levels in ob/ob mice.
Jetton TL; Liang Y; Cincotta AH
Metabolism; 2001 Nov; 50(11):1377-84. PubMed ID: 11699060
[TBL] [Abstract][Full Text] [Related]
2. Dopamine agonist treatment ameliorates hyperglycemia, hyperlipidemia, and the elevated basal insulin release from islets of ob/ob mice.
Liang Y; Lubkin M; Sheng H; Scislowski PW; Cincotta AH
Biochim Biophys Acta; 1998 Oct; 1405(1-3):1-13. PubMed ID: 9784590
[TBL] [Abstract][Full Text] [Related]
3. Differential target molecules for toxicity induced by streptozotocin and alloxan in pancreatic islets of mice in vitro.
Gai W; Schott-Ohly P; Schulte im Walde S; Gleichmann H
Exp Clin Endocrinol Diabetes; 2004 Jan; 112(1):29-37. PubMed ID: 14758569
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of brain-derived neurotrophic factor on pancreatic islets in obese diabetic mice.
Yamanaka M; Itakura Y; Inoue T; Tsuchida A; Nakagawa T; Noguchi H; Taiji M
Metabolism; 2006 Oct; 55(10):1286-92. PubMed ID: 16979397
[TBL] [Abstract][Full Text] [Related]
5. Glucose and insulin regulate glycosylphosphatidylinositol-specific phospholipase D expression in islet beta cells.
Bowen RF; Raikwar NS; Olson LK; Deeg MA
Metabolism; 2001 Dec; 50(12):1489-92. PubMed ID: 11735099
[TBL] [Abstract][Full Text] [Related]
6. Bromocriptine/SKF38393 ameliorates islet dysfunction in the diabetic (db/db) mouse.
Liang Y; Jetton TL; Lubkin M; Meier AH; Cincotta AH
Cell Mol Life Sci; 1998 Jul; 54(7):703-11. PubMed ID: 9711236
[TBL] [Abstract][Full Text] [Related]
7. Insulin and GLUT2 glucose transporter immunoreactivity in B-cells of whole pancreas isografts and allografts in the streptozotocin-diabetic rat.
Jörns A; Klempnauer J
Exp Clin Endocrinol Diabetes; 1995; 103 Suppl 2():103-6. PubMed ID: 8839264
[TBL] [Abstract][Full Text] [Related]
8. Did the gradual loss of GLUT2 cause a shift to diabetic disorders in the New Zealand obese mouse (NZO/Hl)?
Chankiewitz E; Peschke D; Herberg L; Bazwinsky I; Mühlbauer E; Brömme HJ; Peschke E
Exp Clin Endocrinol Diabetes; 2006 May; 114(5):262-9. PubMed ID: 16804801
[TBL] [Abstract][Full Text] [Related]
9. Loss of glucose transporter-2 precedes insulin loss in the nonobese diabetic and the low-dose streptozotocin mouse models: a comparative immunohistochemical study by light and confocal microscopy.
Reddy S; Young M; Poole CA; Ross JM
Gen Comp Endocrinol; 1998 Jul; 111(1):9-19. PubMed ID: 9653017
[TBL] [Abstract][Full Text] [Related]
10. Histological, immunocytochemical, and morphometrical analyses of pancreatic islets in the BSB mouse model of obesity.
Slavin BG; Zarow C; Warden CH; Fisler JS
Anat Rec (Hoboken); 2010 Jan; 293(1):108-16. PubMed ID: 19798700
[TBL] [Abstract][Full Text] [Related]
11. Increased responsiveness to the hyperglycemic, hyperglucagonemic and hyperinsulinemic effects of circulating norepinephrine in ob/ob mice.
Liang Y; Cincotta AH
Int J Obes Relat Metab Disord; 2001 May; 25(5):698-704. PubMed ID: 11360153
[TBL] [Abstract][Full Text] [Related]
12. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
[TBL] [Abstract][Full Text] [Related]
13. Differential sensitivity of GLUT1- and GLUT2-expressing beta cells to streptozotocin.
Hosokawa M; Dolci W; Thorens B
Biochem Biophys Res Commun; 2001 Dec; 289(5):1114-7. PubMed ID: 11741307
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice.
Wang Q; Brubaker PL
Diabetologia; 2002 Sep; 45(9):1263-73. PubMed ID: 12242459
[TBL] [Abstract][Full Text] [Related]
15. DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide.
Ahrén B; Winzell MS; Wierup N; Sundler F; Burkey B; Hughes TE
Regul Pept; 2007 Oct; 143(1-3):97-103. PubMed ID: 17482289
[TBL] [Abstract][Full Text] [Related]
16. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
Eur J Pharmacol; 2008 Jul; 588(2-3):325-32. PubMed ID: 18499100
[TBL] [Abstract][Full Text] [Related]
17. Detrimental effect of protracted hyperglycaemia on beta-cell neogenesis in a mouse murine model of diabetes.
Guz Y; Torres A; Teitelman G
Diabetologia; 2002 Dec; 45(12):1689-96. PubMed ID: 12488958
[TBL] [Abstract][Full Text] [Related]
18. A morphological and immunohistochemical investigation of endocrine pancreata from obese ob+/ob+ mice.
Starich GH; Zafirova M; Jablenska R; Petkov P; Lardinois CK
Acta Histochem; 1991; 90(1):93-101. PubMed ID: 1675542
[TBL] [Abstract][Full Text] [Related]
19. Estrogenic restoration of functional pancreatic islet cytoarchitecture in diabetes (db/db) mutant C57BL/KsJ mice: relationship to estradiol localization, systemic glycemia, and persistent hyperinsulinemia.
Garris DR; Garris BL
Cell Tissue Res; 2005 Feb; 319(2):231-42. PubMed ID: 15654653
[TBL] [Abstract][Full Text] [Related]
20. Increased islet cell proliferation, decreased apoptosis, and greater vascularization leading to beta-cell hyperplasia in mutant mice lacking insulin.
Duvillié B; Currie C; Chrones T; Bucchini D; Jami J; Joshi RL; Hill DJ
Endocrinology; 2002 Apr; 143(4):1530-7. PubMed ID: 11897712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
